With Cell & Gene, Ori’s CCO, Thomas Heathman, Director, Technical Solutions, Keara Trinkle, and Jeffrey Cram, Senior Director, Cellular Process Development at ElevateBio, will speak at our webinar on August 6, at 11:00 ET.
In this webinar, Oribiotech and ElevateBio will share how an automated, scalable CGT platform is reshaping CGT manufacturing, supported by data demonstrating superior biological performance compared to legacy systems. Advanced platforms like IRO are exemplifying this shift by automating critical steps and integrating real-time monitoring while decreasing high production costs, variability in product quality, and the complexity of cell therapy manufacturing workflows.
By leveraging next-generation platforms, therapy developers will be able to scale with confidence, ensuring quality and consistency from early-stage development through commercial manufacturing.
Key Learning Objectives
- Learn how IRO improves biological performance, evaluating growth kinetics, transduction, metabolism, and phenotype throughout the expansion process vs. legacy systems
- Leverage the operational and economic benefits of adopting closed systems for faster clinical and commercial scale-up
- Understand how early technology integration can accelerate scalable, quality-driven CGT manufacturing